Immunotherapy: Immune-modified response criteria — an iterative learning process?
Immunotherapy: Immune-modified response criteria — an iterative learning process?, Published online: 13 March 2018; doi:10.1038/nrclinonc.2018.36Patients with solid tumours can have unusual patterns of response to anticancer immunotherapy, necessitating the adaptation of traditional response criteria. A recent retrospective analysis of data from patients with four different types of solid tumours treated with the anti-programmed cell death 1 ligand 1 (PD-L1) antibody atezolizumab confirms the previous experience in patients with melanoma and provides several new insights. (Source: Nature Clinical Practice Oncology)
Source: Nature Clinical Practice Oncology - March 13, 2018 Category: Cancer & Oncology Authors: Patrick A. Ott Source Type: research
Melanoma: Time for adjuvant vemurafenib?
Melanoma: Time for adjuvant vemurafenib?, Published online: 13 March 2018; doi:10.1038/nrclinonc.2018.39Melanoma: Time for adjuvant vemurafenib? (Source: Nature Clinical Practice Oncology)
Source: Nature Clinical Practice Oncology - March 13, 2018 Category: Cancer & Oncology Authors: Diana Romero Source Type: research
Sarcoma: Local hyperthermia improves survival
Sarcoma: Local hyperthermia improves survival, Published online: 06 March 2018; doi:10.1038/nrclinonc.2018.38Sarcoma: Local hyperthermia improves survival (Source: Nature Clinical Practice Oncology)
Source: Nature Clinical Practice Oncology - March 6, 2018 Category: Cancer & Oncology Authors: David Killock Source Type: research
Targeting the PI3K pathway in cancer: are we making headway?
Targeting the PI3K pathway in cancer: are we making headway?, Published online: 06 March 2018; doi:10.1038/nrclinonc.2018.28The PI3K–AKT–mTOR pathway has key roles in tumorigenesis and is dysregulated in most cancers. Consequently, numerous drugs that target key nodes of this pathway have been developed, although few of these agents have been approved for the treatment of cancer. Herein, the authors review the current experience with anticancer therapies that target the PI3K–AKT–mTOR pathway, discuss the challenges that have limited the clinical translation of these agents, and provide perspectives for the future d...
Source: Nature Clinical Practice Oncology - March 6, 2018 Category: Cancer & Oncology Authors: Filip Janku Timothy A. Yap Funda Meric-Bernstam Source Type: research
Breast cancer: Fibroblast subtypes alter the microenvironment
Breast cancer: Fibroblast subtypes alter the microenvironment, Published online: 06 March 2018; doi:10.1038/nrclinonc.2018.37Breast cancer: Fibroblast subtypes alter the microenvironment (Source: Nature Clinical Practice Oncology)
Source: Nature Clinical Practice Oncology - March 6, 2018 Category: Cancer & Oncology Authors: Peter Sidaway Source Type: research
Immunotherapy: Inhibition of TGFβ enhances immune-checkpoint blockade
Immunotherapy: Inhibition of TGFβ enhances immune-checkpoint blockade, Published online: 06 March 2018; doi:10.1038/nrclinonc.2018.35Immunotherapy: Inhibition of TGFβ enhances immune-checkpoint blockade (Source: Nature Clinical Practice Oncology)
Source: Nature Clinical Practice Oncology - March 6, 2018 Category: Cancer & Oncology Authors: Diana Romero Source Type: research
Enhancing cancer immunotherapy using antiangiogenics: opportunities and challenges
Enhancing cancer immunotherapy using antiangiogenics: opportunities and challenges, Published online: 06 March 2018; doi:10.1038/nrclinonc.2018.29The aberrant tumour vasculature and the associated angiogenic factors have been implicated in tumour immune evasion and progression. Herein, the authors provide their perspectives on how normalization of the tumour microenvironment using antiangiogenic agents could potentially increase the effectiveness of immunotherapies and improve the outcomes of patients with cancer. The authors also highlight important considerations for future research in this area. (Source: Nature Clinical Practice Oncology)
Source: Nature Clinical Practice Oncology - March 6, 2018 Category: Cancer & Oncology Authors: Dai Fukumura Jonas Kloepper Zohreh Amoozgar Dan G. Duda Rakesh K. Jain Source Type: research
CNS cancer: Oncolytic adenovirus effective in patients with glioblastoma
CNS cancer: Oncolytic adenovirus effective in patients with glioblastoma, Published online: 27 February 2018; doi:10.1038/nrclinonc.2018.34CNS cancer: Oncolytic adenovirus effective in patients with glioblastoma (Source: Nature Clinical Practice Oncology)
Source: Nature Clinical Practice Oncology - February 27, 2018 Category: Cancer & Oncology Authors: Peter Sidaway Source Type: research
Epigenome-based cancer risk prediction: rationale, opportunities and challenges
Epigenome-based cancer risk prediction: rationale, opportunities and challenges, Published online: 27 February 2018; doi:10.1038/nrclinonc.2018.30The development of cancer involves several epigenomic alterations, and the presence of certain alterations before the development of cancer is associated with cancer risk. In this Review, the authors describe the potential of epigenomics-based assays to predict an individual's risk of cancer, including discussions of technical, practical and societal issues regarding the implementation of such assays. (Source: Nature Clinical Practice Oncology)
Source: Nature Clinical Practice Oncology - February 27, 2018 Category: Cancer & Oncology Authors: Martin Widschwendter Allison Jones Iona Evans Daniel Reisel Joakim Dillner Karin Sundstr öm Ewout W. Steyerberg Yvonne Vergouwe Odette Wegwarth Felix G. Rebitschek Uwe Siebert Gaby Sroczynski Inez D. de Beaufort Ineke Bolt David Cibula Michal Zikan Line Source Type: research
Breast cancer: Metronomic chemotherapy for elderly and/or frail patients
Breast cancer: Metronomic chemotherapy for elderly and/or frail patients, Published online: 27 February 2018; doi:10.1038/nrclinonc.2018.33Breast cancer: Metronomic chemotherapy for elderly and/or frail patients (Source: Nature Clinical Practice Oncology)
Source: Nature Clinical Practice Oncology - February 27, 2018 Category: Cancer & Oncology Authors: Diana Romero Source Type: research
Health policy: Towards greater equity in the global oncology workforce
Health policy: Towards greater equity in the global oncology workforce, Published online: 27 February 2018; doi:10.1038/nrclinonc.2018.31Despite the rising incidence of cancer in low-income and lower-middle-income countries, very few oncologists are present in these regions — or, in some areas, even none. However, limited evidence of the global oncology workload inequity is available in the literature. Herein, we summarize recent findings that shed some light on this problem and discuss potential oncology workforce solutions. (Source: Nature Clinical Practice Oncology)
Source: Nature Clinical Practice Oncology - February 27, 2018 Category: Cancer & Oncology Authors: Temidayo Fadelu Lawrence N. Shulman Source Type: research
Immunotherapy: CAR T cell therapy efficacious against B-ALL across age groups
Immunotherapy: CAR T cell therapy efficacious against B-ALL across age groups, Published online: 20 February 2018; doi:10.1038/nrclinonc.2018.32Immunotherapy: CAR T cell therapy efficacious against B-ALL across age groups (Source: Nature Clinical Practice Oncology)
Source: Nature Clinical Practice Oncology - February 20, 2018 Category: Cancer & Oncology Authors: Peter Sidaway Source Type: research
Immunotherapy: Cancer immunotherapy and the value of cure
Immunotherapy: Cancer immunotherapy and the value of cure, Published online: 20 February 2018; doi:10.1038/nrclinonc.2018.27Patients value anticancer therapies that provide durable clinical responses; immune-checkpoint inhibitors can provide such benefit for patients with some advanced-stage malignancies, albeit only for a minority of those treated. Modern oncology value frameworks have set efficacy thresholds in an attempt to assess the clinical benefit of anticancer therapeutics. But, is the benefit of durable cancer control reflected in these thresholds? (Source: Nature Clinical Practice Oncology)
Source: Nature Clinical Practice Oncology - February 20, 2018 Category: Cancer & Oncology Authors: Joseph C. Del Paggio Source Type: research
Improving immunotherapy outcomes with anti-angiogenic treatments and vice versa
Improving immunotherapy outcomes with anti-angiogenic treatments and vice versa, Published online: 13 February 2018; doi:10.1038/nrclinonc.2018.9The combination of immunotherapies with other therapeutic modalities, including anti-angiogenic agents, is currently under investigation to improve the outcomes of patients receiving immunotherapies. In this article, the authors review the effects mediated by anti-angiogenic agents that might increase the efficacy of immunotherapies and discuss the possibility that immunotherapies might increase the efficacy of anti-angiogenic agents and/or promote changes in the tumour vasculatur...
Source: Nature Clinical Practice Oncology - February 13, 2018 Category: Cancer & Oncology Authors: Kabir A. Khan Robert S. Kerbel Source Type: research
Toxicity management after chimeric antigen receptor T cell therapy: one size does not fit 'ALL'
Toxicity management after chimeric antigen receptor T cell therapy: one size does not fit 'ALL', Published online: 13 February 2018; doi:10.1038/nrclinonc.2018.20Toxicity management after chimeric antigen receptor T cell therapy: one size does not fit 'ALL' (Source: Nature Clinical Practice Oncology)
Source: Nature Clinical Practice Oncology - February 13, 2018 Category: Cancer & Oncology Authors: Sattva S. Neelapu Sudhakar Tummala Partow Kebriaei William Wierda Frederick L. Locke Yi Lin Nitin Jain Naval Daver Alison M. Gulbis Sherry Adkins Katayoun Rezvani Patrick Hwu Elizabeth J. Shpall Source Type: research
